Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
183 Leser
Artikel bewerten:
(1)

ClearCut Medical Announces Results of a Post Marketing ClearCoast Study Presented at the San Antonio Breast Cancer Symposium

Finanznachrichten News

ClearCoast is the only Portable MRI system that provides real time intraoperative objective, quantitative, and immediately actionable information on margin malignancy assessment during Breast Conserving Surgery

REHOVOT, Israel, Jan. 8, 2025 /PRNewswire/ -- ClearCut Medical, a commercial stage privately held company, developed the ClearCoast, the first and only portable MRI system that performs real-time intraoperative margin assessment of excised breast tumors during Breast Conserving Surgery (BCS). Clear margins are critical in order to minimize the risk of recurrence and the need for retreatment.

ClearCoast portable MRI system that provides the surgeon real time information on margin assessment during Breast Conserving Surgery, developed by ClearCut Medical Ltd.

The study aimed primarily to compare retreatment proportion within and between study groups with accordance to the SSO-ASTRO guideline. The secondary endpoint compared ClearCoast and the Standard of Care (SoC) diagnostic ability to detect positive margins intraoperatively, as well as the total excised breast tissue volume between study groups.

"ClearCoast is the most promising technique currently available for intraoperative margin assessment in breast conserving surgery of in situ and invasive breast cancer" said Prof. Dr. Marc Thill, director of the Department of Gynecology and Gynecological Oncology at the Agaplesion Markus Hospital in Frankfurt, Germany and PI of the study. "Following previous trials and after using the technique in our interventional post-marketing ClearCoast study, I am convinced that the technique is ready for clinical routine."

ClearCoast demonstrated a sensitivity of 81% and a specificity of 70%. It detected 92% of the DCIS compared to 18% in the control group. Moreover, the surgeon removed less breast tissue (69.9cm3 vs. 153.2 cm3) without increasing the duration of the procedure. Lastly, ClearCoast showed a potential for an 80% reduction in re-excisions.

"These results emphasize its potential in reducing the burden of re-excision for patients and the Healthcare costs without trading off time for precision", said Hezi Himelfarb, CEO of ClearCut Medical. "The intuitive display of the system produces images that can be immediately interpreted by the surgeon, without the need for other specialists."

The system received CE Mark approval and is being sold in Europe by pfm medical gmbh.

About Clear-Cut Medical

Clear-Cut Medical is dedicated to improve the quality of care for cancer patients using MRI, the trusted gold-standard imaging modality for cancer diagnostics.

The company developed the ClearCoast, a powerful 1.2T MRI system used to assess the margin of the lumpectomy specimen that is encased in a proprietary disposable chamber inserted into the system. It is fully shielded with no special facility requirements or interference with other instruments in the OR, and provides real-time quantitative information in an intuitive topographic display that is interpreted by the surgeon with no need for additional experts.

The surgeon can instantly identify marginal areas suspected to be malignant and proceed to remove immediately additional tissue before sending the specimen to pathology and by this, reduce significantly the re-excision rate.

The system utilizes state-of-the-art proprietary MRI technology for real time tissue margin assessment. Clinical trial results in BCS have shown high sensitivity and specificity and a potential reduction in re-excision of up to 80%.

Contact:
Hezi Himelfarb
hezi@clrcut.com

Photo - https://mma.prnewswire.com/media/2589546/ClearCoast_MRI_System.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/clearcut-medical-announces-results-of-a-post-marketing-clearcoast-study-presented-at-the-san-antonio-breast-cancer-symposium-302345603.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.